Alliance
C4U enters into Non-Exclusive Sublicense Agreement with Rege Nephro
C4U and Rege Nephro have entered into a non-exclusive agreement, granting Rege Nephro the right to manufacture and sell cells induced to differentiate from PKD1 gene knockout induced pluripotent stem cells (iPS cells). Rege Nephro uses CRISPR-Cas3 technology to produce such PKD1 gene knockout iPS cells, and their product will be used for the discovery of new therapeutic agents to cure Autosomal Dominant (overt) Multiple Cystic Kidney Disease (ADPKD).